Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Asian Growth Stocks With High Insider Ownership In April 2025

In This Article:

As global markets navigate a landscape marked by trade uncertainties and monetary policy shifts, Asia's economic resilience continues to capture investor attention. In this environment, growth companies with high insider ownership can offer appealing insights into potential stability and alignment of interests between management and shareholders.

Top 10 Growth Companies With High Insider Ownership In Asia

Name

Insider Ownership

Earnings Growth

Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)

23.3%

26%

AcrelLtd (SZSE:300286)

40%

32%

WinWay Technology (TWSE:6515)

22.1%

21.4%

Shanghai Huace Navigation Technology (SZSE:300627)

24.7%

24.4%

Seojin SystemLtd (KOSDAQ:A178320)

32.1%

39.3%

Laopu Gold (SEHK:6181)

36.4%

40.2%

Global Tax Free (KOSDAQ:A204620)

20.8%

35.1%

Zhejiang Leapmotor Technology (SEHK:9863)

15.2%

61.9%

Fulin Precision (SZSE:300432)

13.6%

74.7%

Offcn Education Technology (SZSE:002607)

26.1%

93.3%

Click here to see the full list of 645 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Akeso

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of antibody drugs with a market cap of HK$74.45 billion.

Operations: The company's revenue segment primarily consists of CN¥2.12 billion from the research, development, production, and sale of biopharmaceutical products.

Insider Ownership: 19%

Akeso is strategically positioned in the Asian market with significant insider ownership, enhancing its alignment with shareholder interests. Despite a recent revenue decline to CNY 2.12 billion and a net loss of CNY 514.52 million, Akeso's innovative pipeline shows strong growth potential. The company forecasts robust annual revenue growth of 28.9% and expects profitability within three years, supported by recent regulatory approvals for key treatments like penpulimab and ivonescimab, which are pivotal in expanding its oncology portfolio globally.

SEHK:9926 Earnings and Revenue Growth as at Apr 2025
SEHK:9926 Earnings and Revenue Growth as at Apr 2025

BIWIN Storage Technology

Simply Wall St Growth Rating: ★★★★★★

Overview: BIWIN Storage Technology Co., Ltd. engages in the research, development, design, packaging, testing, production, and sale of semiconductor memories with a market cap of CN¥27.85 billion.

Operations: The company generates revenue primarily from its semiconductor segment, amounting to CN¥6.70 billion.